BeStock  

Amylyx Pharmaceuticals AMLX

US equityMarket cap rank #2350Drug Manufacturers - Specialty & Generic
$26.02 −$0.18 (-0.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.55 -1.81%
Open$25.64
Prev close$26.20
Day range$25.52 – $26.40
Volume1.14M
Market cap$3.35B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$49.66M-37.8% YoY
Net profit-$45.49M-32.3% YoY
Diluted EPS-$0.38-2.7% YoY
Free cash flow-$33.70M-10.9% YoY
Operating cash flow-$33.67M

Revenue, last 8 quarters

$-665.0KDec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-37.5MDec '24$-35.9MMar '25$-41.4MJun '25$-34.4MSep '25$-33.0MDec '25$-41.3MMar '26$-43.4MJun '26$-45.5MSep '26

Diluted EPS by quarter

-0.55Dec '24-0.42Mar '25-0.46Jun '25-0.37Sep '25-0.30Dec '25-0.37Mar '26-0.39Jun '26-0.38Sep '26

Free cash flow by quarter

$-59.0MDec '24$-39.8MMar '25$-25.3MJun '25$-30.4MSep '25$-28.0MDec '25$-36.9MMar '26$-31.5MJun '26$-33.7MSep '26

Annual revenue

$0.0FY20$0.0FY21$22.2MFY22$380.8MFY23$87.4MFY24$0.0FY25

Profitability & balance sheet

Return on equity-30.1%
Return on assets-28.4%
Return on invested capital-32.0%
Current ratio26.81
Liabilities / assets4.2%
Cash & investments$768.13M
Total debt$4.01M
Net cash (debt)$764.12M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $49.66M $45.69M $43.78M $153.29M $36.61M
Selling and Admin Expenses $21.31M $21.93M $16.17M $62.89M $15.39M
Research & Development $28.35M $23.77M $27.61M $90.40M $21.21M
Operating Profit -$49.66M -$45.69M -$43.78M -$153.29M -$36.61M
Net Non-Operating Interest Income (Expense) $4.18M $2.32M $2.57M $9.30M $3.29M
Non-Operating Interest Income $4.18M $2.32M $2.57M $9.30M $3.29M
Other Income (Expense) -$14,000.00 -$53,000.00 -$75,000.00 -$700,000.00 $362,000.00
Other Non-Operating Income (Expenses) -$14,000.00 -$53,000.00 -$75,000.00 -$700,000.00 $362,000.00
Pretax Profit -$45.49M -$43.42M -$41.28M -$144.69M -$32.95M
Net Profit -$45.49M -$43.42M -$41.28M -$144.74M -$33.00M
Profit from Continuing Operations -$45.49M -$43.42M -$41.28M -$144.74M -$33.00M
Net Income to Parent Company -$45.49M -$43.42M -$41.28M -$144.74M -$33.00M
Net Income to Common Stockholders -$45.49M -$43.42M -$41.28M -$144.74M -$33.00M
Basic EPS -$0.38 -$0.39 -$0.37 -$1.53 -$0.30
Diluted EPS -$0.38 -$0.39 -$0.37 -$1.53 -$0.30
Total Revenue as Reported – – $0.00 $0.00 $0.00
Cost of Revenue – – $0.00 $0.00 $0.00
Gross Profit – – $0.00 $0.00 $0.00
Special Income (Charges) – – – $0.00 $0.00
-Less:Restructuring and Mergern & Acquisition – – – $0.00 $0.00
Tax – – – $46,000.00 $46,000.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $786.80M $264.56M $293.60M $332.65M $332.65M
Total Current Assets $778.86M $256.34M $285.02M $323.67M $323.67M
Cash and Cash Equivalents & Short-Term Investments $768.13M $250.76M $279.77M $316.98M $316.98M
-Cash and Cash Equivalents $240.10M $49.33M $229.14M $226.65M $226.65M
-Short Term Investments $528.04M $201.43M $50.63M $90.33M $90.33M
Other Current Assets $10.73M $5.58M $5.26M $6.60M $6.60M
Total Non-Current Assets $7.94M $8.23M $8.58M $8.97M $8.97M
Net PPE $4.44M $4.74M $5.09M $5.49M $5.49M
-Gross PPE $4.44M $4.74M $5.09M $7.05M $7.05M
Other Non-Current Assets $3.50M $3.49M $3.49M $3.48M $3.48M
Total Liabilities $33.06M $25.40M $20.44M $27.39M $27.39M
Total Current Liabilities $29.05M $21.15M $15.97M $22.69M $22.69M
Payables $4.80M $5.53M $3.53M $3.52M $3.52M
-Accounts Payable $4.80M $5.53M $3.53M $3.52M $3.52M
Current Accrued Expenses $13.86M $8.98M $8.09M $7.86M $7.86M
Short-Term Debt and Capital Lease Obligation $932,000.00 $1.01M $1.16M $1.26M $1.26M
-Current Capital Lease Obligation $932,000.00 $1.01M $1.16M $1.26M $1.26M
Total Non-Current Liabilities $4.01M $4.25M $4.48M $4.70M $4.70M
Long Term Debt and Capital Lease Obligation $4.01M $4.25M $4.48M $4.70M $4.70M
-Long Term Capital Lease Obligation $4.01M $4.25M $4.48M $4.70M $4.70M
Total Equity $753.74M $239.17M $273.16M $305.26M $305.26M
Stockholders' Equity $753.74M $239.17M $273.16M $305.26M $305.26M
Capital Stock $13,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Common Stock $13,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Preferred Stock $0.00 $0.00 $0.00 – –
Additional Paid-In Capital $1.64B $1.08B $1.07B $1.06B $1.06B
Retained Earnings -$881.62M -$836.13M -$792.71M -$751.43M -$751.43M
Gains/Losses Not Affecting Retained Earnings -$179,000.00 $19,000.00 $240,000.00 $404,000.00 $404,000.00
Receivables – – – $88,000.00 $88,000.00
-Accounts Receivable – – – $88,000.00 $88,000.00
-Accumulated Depreciation – – – -$1.55M -$1.55M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$33.67M -$31.42M -$36.88M -$123.34M -$27.90M
Net cash flow from continuing operations -$33.67M -$31.42M -$36.88M -$123.34M -$27.90M
Net Income from Continuing Operations -$45.49M -$43.42M -$41.28M -$144.74M -$33.00M
Depreciation & Depletion & Amortization $33,000.00 $43,000.00 $98,000.00 $525,000.00 $108,000.00
Other Non-Cash Items -$9,000.00 $31,000.00 $4.05M -$169,000.00 -$433,000.00
Change in Working Capital $2.53M $4.82M -$5.26M -$1.08M $92,000.00
-Change in Prepaid Assets -$5.15M -$325,000.00 $1.43M $3.98M $325,000.00
-Change in Payables and Accrued Expense $7.70M $5.18M -$6.66M -$6.02M -$934,000.00
-Change in Other Current Assets $294,000.00 $340,000.00 $298,000.00 $1.73M $295,000.00
-Change in Other Current Liabilities -$312,000.00 -$375,000.00 -$327,000.00 -$1.16M $23,000.00
Net cash flow from investing -$325.67M -$149.80M $36.26M $14.04M $29.47M
Net Cash Flow from Continuing Investing Activities -$325.67M -$149.80M $36.26M $14.04M $29.47M
Net PPE Purchase and Sale -$25,000.00 -$30,000.00 $0.00 -$138,000.00 -$86,000.00
Net Investment Purchase and Sale -$325.64M -$149.77M $40.26M $14.18M $29.55M
Net Other Investing Changes $0.00 $0.00 -$4.00M – –
Financing Cash Flow $550.16M $1.48M $3.22M $257.03M -$208,000.00
Net Cash Flow from Continuing Financing Activities $550.16M $1.48M $3.22M $257.03M -$208,000.00
Proceeds from Stock Option Exercised $11.71M $1.97M $7.16M $4.08M $376,000.00
Net Other Financing Charges $538.45M -$494,000.00 -$3.94M $252.95M -$584,000.00
Ending Cash Balance $241.09M $50.31M $230.12M $227.64M $227.64M
Net Change in Cash $190.82M -$179.74M $2.60M $147.73M $1.36M
Beginning Cash Balance $50.31M $230.12M $227.64M $78.84M $226.16M
Effect of Exchange Rate Changes -$39,000.00 -$68,000.00 -$111,000.00 $1.07M $118,000.00
Free Cash Flow -$33.70M -$31.45M -$36.88M -$123.48M -$27.99M
-Change in Receivables – – – $383,000.00 $50,000.00
-Change in Inventory – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on AMLX.

Sign in to join the discussion.

Scroll to Top